Call +44 (0)1904 798634 or +44 (0)7550 079918

Leading provider of life science market reports and research services

Items 1 to 10 of 46 total

Set Descending Direction
per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Top 20 orphan drugs by 2018

03/02/2014 23:42

For a long time, pharma companies have looked to large disease populations as the biggest potential revenue streams. But those days are long gone. That perception has shifted, especially with the pres...Read More
Comments | Posted By Claire Nicholson

Global public health campaigns offer great potential to raise awareness and understanding about health issues and mobilize support for action, from the local community to the international stage. Ther...

Read More

Tags:

Comments | Posted By Claire Nicholson

The orphan drug maker has found a home for some of its operations in the low-tax country The tax advantages of doing business in Ireland have been plumbed by a number of drugmakers, some of whom have ...

Read More

Tags:

Comments | Posted By Claire Nicholson

Ten companies will pool data in an effort to identify promising drug targets for Alzheimer's disease, lupus and diabetes treatments.

 

Pharmaceutical companies spend billions of dollars each year develo...

Read More
Comments | Posted By Claire Nicholson

Furiex Pharmaceuticals, Inc. (FURX) has announced top-line results indicating the company’s two pivotal Phase III clinical trials evaluating the efficacy and safety of eluxadoline in the treatment of ...

Read More
Comments | Posted By Claire Nicholson

 2018, it is estimated that the global pharmaceutical market will be worth more than $1.3 trillion USD. To corner their share of profits, established drug companies have to fight fierce competition fr...

Read More
Comments | Posted in Articles By Claire Nicholson

Are the BRIC countries passé in Big Pharma? Not exactly. Brazil, Russia, India and China aren't the great shining frontiers they used to be, but they're still on most drugmakers' to-do lists.

The lates...

Read More

Tags:

Comments | Posted By Claire Nicholson

Furiex Pharmaceuticals Inc. (FURX), the drug developer whose irritable bowel treatment is moving toward regulatory approval, is working with Bank of America Corp. to find a buyer, people with knowledg...

Read More
Comments | Posted By Claire Nicholson

Purchase the report: Emerging Biotech Investment Report - Strategic Trends in Private Equity and Venture Capital Funding

 

The importance of capital, particularly for emerging biotechnology firms, canno...

Read More
Comments | Posted in Articles By Claire Nicholson

Items 1 to 10 of 46 total

Set Descending Direction
per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5